Table 3.
Clinicopathologic parameters | Outcome
|
P-value | |
---|---|---|---|
Remission | Relapse | ||
Sex | 0.432 | ||
Male | 26 | 5 | |
Female | 25 | 2 | |
Age (years) | 1.000 | ||
≤40 | 25 | 3 | |
>40 | 26 | 4 | |
WBC count (×109/L) | 0.592 | ||
≤5 | 43 | 5 | |
>5 | 8 | 2 | |
Platelet count (×109/L) | 0.661 | ||
≤40 | 35 | 6 | |
>40 | 16 | 1 | |
Hemoglobin (g/L) | 0.083 | ||
<100 | 39 | 3 | |
≥100 | 12 | 4 | |
Induction regimens | 0.327 | ||
ATRA+As2O3+IDA | 11 | 0 | |
ATRA+IDA | 40 | 7 | |
Maintenance regimens | 0.004 | ||
ATRA+As2O3 | 30 | 0 | |
ATRA+chemotherapy | 21 | 7 |
Abbreviations: APL, acute promyelocytic leukemia; As2O3, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; WBC, white blood cell.